Cytokine profiling of prostatic fluid from cancerous prostate glands identifies cytokines associated with extent of tumor and inflammation

Prostate

Volumn 68, Issue 8, 2008, Pages 872-882

  Fujita, Kazutoshi ^a   Ewing, Charles M ^a   Sokoll, Lori J ^a   Elliott, Debra J ^a   Cunningham, Mark ^a   De Marzo, Angelo M ^a   Isaacs, William B ^a   Pavlovich, Christian P ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cancer; Cytokine; Inflammation

Indexed keywords

CYTOKINE; CYTOKINE ANTIBODY; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 18;

ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; HUMAN; HUMAN TISSUE; INFLAMMATION; LYMPHOCYTE; MACROPHAGE; MALE; MICROARRAY ANALYSIS; NEUTROPHIL; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE FLUID; PROSTATE INFLAMMATION; PROSTATECTOMY; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; STROMA; TUMOR VOLUME; URINALYSIS;

BODY FLUIDS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPATOCYTE GROWTH FACTOR; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PROSTATE; PROSTATIC NEOPLASMS; PROSTATITIS; PROTEIN ARRAY ANALYSIS;

EID: 45349106917     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20755     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2007;57(1):43-66.
2. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7(4):256-269.
3. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis. Am J Pathol 1999;155(6):1985-1992.
4. Cohen RJ, Shannon BA, McNeal JE, Shannon T, Garrett KL. Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: A possible link to cancer evolution? J Urol 2005;173(6):1969-1974.
5. Hochreiter WW, Nadler RB, Koch AE, Campbell PL, Ludwig M, Weidner W, Schaeffer AJ. Evaluation of the cytokines interleukin 8 and epithelial neutrophil activating peptide 78 as indicators of inflammation in prostatic secretions. Urology 2000;56(6):1025-1029.
6. Gann PH, Klein KG, Chatterton RT, Ellman AE, Grayhack JT, Nadler RB, Lee C. Growth factors in expressed prostatic fluid from men with prostate cancer, BPH, and clinically normal prostates. Prostate 1999;40(4):248-255.
7. Allan RW, Sanderson H, Epstein JI. Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: Role of prostate specific antigen density. J Urol 2003;170(2 Pt 1):370-372.
8. Nickel JC, True LD, Krieger JN, Berger RE, Boag AH, Young ID. Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU Int 2001;87(9):797-805.
9. Nishimura K, Kitamura M, Miura H, Nonomura N, Takada S, Takahara S, Matsumoto K, Nakamura T, Matsumiya K. Prostate stromal cell-derived hepatocyte growth factor induces invasion of prostate cancer cell line DU145 through tumor-stromal interaction. Prostate 1999;41(3):145-153.
10. Weeraratna AT, Arnold JT, George DJ, DeMarzo A, Isaacs JT. Rational basis for Trk inhibition therapy for prostate cancer. Prostate 2000;45(2):140-148.
11. Lu S, Dong Z. Characterization of TGF-beta-regulated interleukin-8 expression in human prostate cancer cells. Prostate 2006;66(9):996-1004.
12. Steiner GE, Djavan B, Kramer G, Handisurya A, Newman M, Lee C, Marberger M. The picture of the prostatic lymphokine network is becoming increasingly complex. Rev Urol 2002;4(4):171-177.
13. Ao M, Franco OE, Park D, Raman D, Williams K, Hayward SW. Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res 2007;67(9):4244-4253.
14. Hurle RA, Davies G, Parr C, Mason MD, Jenkins SA, Kynaston HG, Jiang WG. Hepatocyte growth factor/scatter factor and prostate cancer: A review. Histol Histopathol 2005;20(4):1339-1349.
15. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002;13(2):155-168.
16. Vidal-Vanaclocha F, Mendoza L, Telleria N, Salado C, Valcarcel M, Gallot N, Carrascal T, Egilegor E, Beaskoetxea J, Dinarello CA. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev 2006;25(3):417-434.
17. Gho YS, Kleinman HK, Sosne G. Angiogenic activity of human soluble intercellular adhesion molecule-1. Cancer Res 1999;59(20)5128-5132.
18. Lynch DF Jr, Hassen W, Clements MA, Schellhammer PF, Wright GL Jr. Serum levels of endothelial and neural cell adhesion molecules in prostate cancer. Prostate 1997;32(3):214-220.
19. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Basham B, McClanahan T, Kastelein RA, Oft M. IL-23 promotes tumour incidence and growth. Nature 2006;442(7101):461-465.
20. Arenberg DA, Keane MP, DiGiovine B, Kunkel SL, Morris SB, Xue YY, Burdick MD, Glass MC, Iannettoni MD, Strieter RM. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J Clin Invest 1998;102(3):465-472.
21. Walz A, Schmutz P, Mueller C, Schnyder-Candrian S. Regulation and function of the CXC chemokine ENA-78 in monocytes and its role in disease. J Leukoc Biol 1997;62(5):604-611.
22. Naughton M, Picus J, Zhu X, Catalona WJ, Vollmer RT, Humphrey PA. Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer. J Urol 2001;165(4):1325-1328.
23. Zhu X, Humphrey PA. Overexpression and regulation of expression of scatter factor/hepatocyte growth factor in prostatic carcinoma. Urology 2000;56(6):1071-1074.
24. Witowski J, Ksiazek K, Jorres A. Interleukin-17: A mediator of inflammatory responses. Cell Mol Life Sci 2004;61(5):567-579.
25. Zen K, Parkos CA. Leukocyte-epithelial interactions. Curr Opin Cell Biol 2003;15(5):557-564.
26. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 2001;19:423-474.
27. Veenstra KG, Jonak ZL, Trulli S, Gollob JA. IL-12 induces monocyte IL-18 binding protein expression via IFN-gamma. J Immunol 2002;168(5):2282-2287.
28. Paulukat J, Bosmann M, Nold M, Garkisch S, Kampfer H, Frank S, Raedle J, Zeuzem S, Pfeilschifter J, Muhl H. Expression and release of IL-18 binding protein in response to IFN-gamma. J Immunol 2001;167(12):7038-7043.
29. Ji HB, Liao G, Faubion WA, Abadia-Molina AC, Cozzo C, Laroux FS, Caton A, Terhorst C. Cutting edge: The natural ligand for glucocorticoid-induced TNF receptor-related protein abrogates regulatory T cell suppression. J Immunol 2004;172(10):5823-5827.
30. Baltz KM, Krusch M, Bringmann A, Brossart P, Mayer F, Kloss M, Baessler T, Kumbier I, Peterfi A, Kupka S, Kroeber S, Menzel D, Radsak MP, Rammensee HG, Salih HR. Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions. FASEB J 2007; 12(10):2442-2454.
31. Cuzzocrea S, Ayroldi E, Di Paola R, Agostini M, Mazzon E, Bruscoli S, Genovese T, Ronchetti S, Caputi AP, Riccardi C. Role of glucocorticoid-induced TNF receptor family gene (GITR) in collagen-induced arthritis. FASEB J 2005;19(10):1253-1265.
32. Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. Nat Immunol 2005;6(4):353-360.
33. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006;108(3):804-811.
34. Albelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury. FASEB J 1994;8(8):504-512.